ERBB2 and cancer: We discussed preclinical and clinical work using HER2-targeted treatments including “naked” antibodies (i.e., trastuzumab and pertuzumab) as well as antibody–drug conjugates (i.e., T-DM1 and T-DXd) in USC models and cancer patients.